JP5329538B2 - 粘膜炎の治療において有用な方法および組成物 - Google Patents

粘膜炎の治療において有用な方法および組成物 Download PDF

Info

Publication number
JP5329538B2
JP5329538B2 JP2010516038A JP2010516038A JP5329538B2 JP 5329538 B2 JP5329538 B2 JP 5329538B2 JP 2010516038 A JP2010516038 A JP 2010516038A JP 2010516038 A JP2010516038 A JP 2010516038A JP 5329538 B2 JP5329538 B2 JP 5329538B2
Authority
JP
Japan
Prior art keywords
mucositis
sap
cancer
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010516038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532787A5 (https=
JP2010532787A (ja
Inventor
デイビッド ポール ヘッソン，
マイケル スコット クレーマー，
Original Assignee
プロメディオール， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/215,700 external-priority patent/US9884899B2/en
Application filed by プロメディオール， インコーポレイテッド filed Critical プロメディオール， インコーポレイテッド
Publication of JP2010532787A publication Critical patent/JP2010532787A/ja
Publication of JP2010532787A5 publication Critical patent/JP2010532787A5/ja
Application granted granted Critical
Publication of JP5329538B2 publication Critical patent/JP5329538B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
JP2010516038A 2007-07-06 2008-07-07 粘膜炎の治療において有用な方法および組成物 Expired - Fee Related JP5329538B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95863407P 2007-07-06 2007-07-06
US60/958,634 2007-07-06
US96134307P 2007-07-20 2007-07-20
US60/961,343 2007-07-20
US12/215,700 US9884899B2 (en) 2007-07-06 2008-06-27 Methods for treating fibrosis using CRP antagonists
US12/215,700 2008-06-27
PCT/US2008/008340 WO2009009034A2 (en) 2007-07-06 2008-07-07 Methods and compositions useful in the treatment of mucositis

Publications (3)

Publication Number Publication Date
JP2010532787A JP2010532787A (ja) 2010-10-14
JP2010532787A5 JP2010532787A5 (https=) 2012-08-16
JP5329538B2 true JP5329538B2 (ja) 2013-10-30

Family

ID=40076757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516038A Expired - Fee Related JP5329538B2 (ja) 2007-07-06 2008-07-07 粘膜炎の治療において有用な方法および組成物

Country Status (9)

Country Link
EP (1) EP2185581B1 (https=)
JP (1) JP5329538B2 (https=)
CA (1) CA2692682C (https=)
DK (1) DK2185581T3 (https=)
ES (1) ES2554167T3 (https=)
HU (1) HUE026850T2 (https=)
PL (1) PL2185581T3 (https=)
PT (1) PT2185581E (https=)
WO (1) WO2009009034A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) * 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
CN105792831A (zh) * 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2158292A (en) * 1991-05-31 1993-01-08 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
AU8351698A (en) * 1997-07-23 1999-02-16 Cleansorb Limited Methods for deposition of materials in underground reservoirs
EP1879597A2 (en) * 2005-05-13 2008-01-23 Eisai Co., Ltd. Lipid a analogs for treating oral and gastrointestinal mucositis
CA2625403A1 (en) * 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases

Also Published As

Publication number Publication date
EP2185581A2 (en) 2010-05-19
CA2692682A1 (en) 2009-01-15
ES2554167T3 (es) 2015-12-16
PT2185581E (pt) 2015-12-09
EP2185581B1 (en) 2015-09-02
WO2009009034A3 (en) 2009-02-26
HUE026850T2 (en) 2016-08-29
PL2185581T3 (pl) 2016-01-29
JP2010532787A (ja) 2010-10-14
DK2185581T3 (en) 2015-12-14
AU2008275693A1 (en) 2009-01-15
WO2009009034A2 (en) 2009-01-15
CA2692682C (en) 2017-05-02

Similar Documents

Publication Publication Date Title
JP5329538B2 (ja) 粘膜炎の治療において有用な方法および組成物
Wang et al. HMGB1 as a late mediator of lethal systemic inflammation
US8497243B2 (en) Methods and compositions useful in the treatment of mucositis
US20130302344A1 (en) Methods and medicaments for the treatment of gout or pseudogout
US11571427B2 (en) Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
JP2022507606A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
CN102448484A (zh) 调节角质化细胞增生和分化的方法
US11993640B2 (en) Treating inflammatory lung disease
TW202039555A (zh) ＩＬ-１β結合抗體之用途
WO2023001304A1 (zh) 预防、缓解或治疗黏膜黏连的药物及其应用
JP2018065814A (ja) Ｈｅｒｖ−ｗエンベロープタンパク質発現関連疾患において再ミエリン化遮断を治療するための化合物
Quinn et al. Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice
Adhyatmika et al. Osteoprotegerin expression in liver is induced by IL13 through TGFβ
Takemoto et al. An herbal medicine, Go-sha-jinki-gan (GJG), increases muscle weight in severe muscle dystrophy model mice
AU2008275693B2 (en) Methods and compositions useful in the treatment of mucositis
CA2709224C (en) Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
Cerqueira et al. BET protein inhibition promotes non-myeloid cell mediated neuroprotection after rodent spinal cord contusion
RU2741228C2 (ru) Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
HK40038930A (en) Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
Luo et al. Stress-induced Premature Promotes Prostate Cancer Growth and Metastasis through Alteration of Microenvironment
EA023383B1 (ru) Способ подавления роста опухоли и лечения заболеваний путем избирательного ингибирования участков рецепторов с тирозинкиназной активностью

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120625

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130724

R150 Certificate of patent or registration of utility model

Ref document number: 5329538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees